UNIVERSAL TECHNICAL INSTITUT (UTI) Fundamental Analysis & Valuation

NYSE:UTI • US9139151040

Current stock price

37.135 USD
-0.4 (-1.05%)
Last:

This UTI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. UTI Profitability Analysis

1.1 Basic Checks

  • In the past year UTI was profitable.
  • UTI had a positive operating cash flow in the past year.
  • In the past 5 years UTI has always been profitable.
  • In the past 5 years UTI always reported a positive cash flow from operatings.
UTI Yearly Net Income VS EBIT VS OCF VS FCFUTI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M

1.2 Ratios

  • UTI has a Return On Assets of 6.44%. This is in the better half of the industry: UTI outperforms 71.23% of its industry peers.
  • Looking at the Return On Equity, with a value of 15.98%, UTI is in the better half of the industry, outperforming 75.34% of the companies in the same industry.
  • With a decent Return On Invested Capital value of 8.69%, UTI is doing good in the industry, outperforming 75.34% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for UTI is significantly below the industry average of 15.24%.
  • The 3 year average ROIC (7.27%) for UTI is below the current ROIC(8.69%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 6.44%
ROE 15.98%
ROIC 8.69%
ROA(3y)4.45%
ROA(5y)3.5%
ROE(3y)11.95%
ROE(5y)9.34%
ROIC(3y)7.27%
ROIC(5y)5.89%
UTI Yearly ROA, ROE, ROICUTI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 -20 -30

1.3 Margins

  • UTI's Profit Margin of 6.28% is fine compared to the rest of the industry. UTI outperforms 64.38% of its industry peers.
  • UTI's Profit Margin has improved in the last couple of years.
  • With a decent Operating Margin value of 8.38%, UTI is doing good in the industry, outperforming 64.38% of the companies in the same industry.
  • UTI's Operating Margin has improved in the last couple of years.
  • UTI has a Gross Margin (49.62%) which is in line with its industry peers.
  • UTI's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 8.38%
PM (TTM) 6.28%
GM 49.62%
OM growth 3Y17.03%
OM growth 5YN/A
PM growth 3Y35.13%
PM growth 5Y53.06%
GM growth 3Y-13.36%
GM growth 5Y-8.21%
UTI Yearly Profit, Operating, Gross MarginsUTI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. UTI Health Analysis

2.1 Basic Checks

  • UTI has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • The number of shares outstanding for UTI has been increased compared to 1 year ago.
  • The number of shares outstanding for UTI has been increased compared to 5 years ago.
  • UTI has a better debt/assets ratio than last year.
UTI Yearly Shares OutstandingUTI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
UTI Yearly Total Debt VS Total AssetsUTI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • An Altman-Z score of 4.03 indicates that UTI is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of UTI (4.03) is better than 79.45% of its industry peers.
  • The Debt to FCF ratio of UTI is 6.28, which is on the high side as it means it would take UTI, 6.28 years of fcf income to pay off all of its debts.
  • UTI has a Debt to FCF ratio of 6.28. This is in the better half of the industry: UTI outperforms 69.86% of its industry peers.
  • A Debt/Equity ratio of 0.29 indicates that UTI is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.29, UTI is in line with its industry, outperforming 56.16% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF 6.28
Altman-Z 4.03
ROIC/WACC0.99
WACC8.82%
UTI Yearly LT Debt VS Equity VS FCFUTI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M

2.3 Liquidity

  • UTI has a Current Ratio of 1.14. This is a normal value and indicates that UTI is financially healthy and should not expect problems in meeting its short term obligations.
  • UTI has a Current ratio of 1.14. This is comparable to the rest of the industry: UTI outperforms 43.84% of its industry peers.
  • UTI has a Quick Ratio of 1.14. This is a normal value and indicates that UTI is financially healthy and should not expect problems in meeting its short term obligations.
  • UTI has a Quick ratio (1.14) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.14
Quick Ratio 1.14
UTI Yearly Current Assets VS Current LiabilitesUTI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. UTI Growth Analysis

3.1 Past

  • UTI shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by 0.00%.
  • UTI shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 65.96% yearly.
  • The Revenue has grown by 12.59% in the past year. This is quite good.
  • Measured over the past years, UTI shows a very strong growth in Revenue. The Revenue has been growing by 22.67% on average per year.
EPS 1Y (TTM)0%
EPS 3Y3.11%
EPS 5Y65.96%
EPS Q2Q%-42.5%
Revenue 1Y (TTM)12.59%
Revenue growth 3Y25.89%
Revenue growth 5Y22.67%
Sales Q2Q%9.64%

3.2 Future

  • Based on estimates for the next years, UTI will show a small growth in Earnings Per Share. The EPS will grow by 5.89% on average per year.
  • The Revenue is expected to grow by 8.84% on average over the next years. This is quite good.
EPS Next Y-31.19%
EPS Next 2Y-10.6%
EPS Next 3Y5.89%
EPS Next 5YN/A
Revenue Next Year9.48%
Revenue Next 2Y8.9%
Revenue Next 3Y8.84%
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
UTI Yearly Revenue VS EstimatesUTI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 200M 400M 600M 800M 1B
UTI Yearly EPS VS EstimatesUTI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 1 -1

More info and screens

Find the best growth stocksShow best growing peers

2

4. UTI Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 38.28 indicates a quite expensive valuation of UTI.
  • UTI's Price/Earnings ratio is in line with the industry average.
  • UTI is valuated rather expensively when we compare the Price/Earnings ratio to 26.77, which is the current average of the S&P500 Index.
  • The Price/Forward Earnings ratio is 40.76, which means the current valuation is very expensive for UTI.
  • UTI's Price/Forward Earnings is on the same level as the industry average.
  • UTI's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 21.75.
Industry RankSector Rank
PE 38.28
Fwd PE 40.76
UTI Price Earnings VS Forward Price EarningsUTI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • UTI's Enterprise Value to EBITDA is on the same level as the industry average.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of UTI is on the same level as its industry peers.
Industry RankSector Rank
P/FCF 126.6
EV/EBITDA 18.33
UTI Per share dataUTI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • UTI has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.58
EPS Next 2Y-10.6%
EPS Next 3Y5.89%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. UTI Dividend Analysis

5.1 Amount

  • UTI does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

UTI Fundamentals: All Metrics, Ratios and Statistics

UNIVERSAL TECHNICAL INSTITUT

NYSE:UTI (5/1/2026, 11:20:05 AM)

37.135

-0.4 (-1.05%)

Chartmill FA Rating
GICS IndustryGroupConsumer Services
GICS IndustryDiversified Consumer Services
Industry Strength9.32
Industry Growth63.35
Earnings (Last)02-04
Earnings (Next)05-06
Inst Owners96.88%
Inst Owner Change3.67%
Ins Owners2.49%
Ins Owner Change3.2%
Market Cap2.04B
Revenue(TTM)855.03M
Net Income(TTM)53.69M
Analysts81.82
Price Target38.42 (3.46%)
Short Float %5.45%
Short Ratio4.04
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.03
Dividend Growth(5Y)-34.43%
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)47.57%
Min EPS beat(2)28.91%
Max EPS beat(2)66.22%
EPS beat(4)4
Avg EPS beat(4)59.42%
Min EPS beat(4)28.91%
Max EPS beat(4)73.27%
EPS beat(8)7
Avg EPS beat(8)48.68%
EPS beat(12)11
Avg EPS beat(12)85.96%
EPS beat(16)14
Avg EPS beat(16)183.11%
Revenue beat(2)2
Avg Revenue beat(2)0.64%
Min Revenue beat(2)0.47%
Max Revenue beat(2)0.82%
Revenue beat(4)4
Avg Revenue beat(4)1.74%
Min Revenue beat(4)0.47%
Max Revenue beat(4)4.51%
Revenue beat(8)8
Avg Revenue beat(8)2.01%
Revenue beat(12)12
Avg Revenue beat(12)2.35%
Revenue beat(16)15
Avg Revenue beat(16)2.9%
PT rev (1m)0%
PT rev (3m)0.64%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-103.86%
EPS NY rev (1m)0%
EPS NY rev (3m)0.72%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.41%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.21%
Valuation
Industry RankSector Rank
PE 38.28
Fwd PE 40.76
P/S 2.39
P/FCF 126.6
P/OCF 26.38
P/B 6.08
P/tB 7.13
EV/EBITDA 18.33
EPS(TTM)0.97
EY2.61%
EPS(NY)0.91
Fwd EY2.45%
FCF(TTM)0.29
FCFY0.79%
OCF(TTM)1.41
OCFY3.79%
SpS15.54
BVpS6.11
TBVpS5.21
PEG (NY)N/A
PEG (5Y)0.58
Graham Number11.5432 (-68.92%)
Profitability
Industry RankSector Rank
ROA 6.44%
ROE 15.98%
ROCE 11.63%
ROIC 8.69%
ROICexc 11.82%
ROICexgc 13.27%
OM 8.38%
PM (TTM) 6.28%
GM 49.62%
FCFM 1.89%
ROA(3y)4.45%
ROA(5y)3.5%
ROE(3y)11.95%
ROE(5y)9.34%
ROIC(3y)7.27%
ROIC(5y)5.89%
ROICexc(3y)10.21%
ROICexc(5y)8.25%
ROICexgc(3y)11.54%
ROICexgc(5y)9.21%
ROCE(3y)9.72%
ROCE(5y)7.88%
ROICexgc growth 3Y34.26%
ROICexgc growth 5YN/A
ROICexc growth 3Y33.76%
ROICexc growth 5YN/A
OM growth 3Y17.03%
OM growth 5YN/A
PM growth 3Y35.13%
PM growth 5Y53.06%
GM growth 3Y-13.36%
GM growth 5Y-8.21%
F-Score7
Asset Turnover1.03
Health
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF 6.28
Debt/EBITDA 0.93
Cap/Depr 181.06%
Cap/Sales 7.17%
Interest Coverage 13.88
Cash Conversion 73.39%
Profit Quality 30.06%
Current Ratio 1.14
Quick Ratio 1.14
Altman-Z 4.03
F-Score7
WACC8.82%
ROIC/WACC0.99
Cap/Depr(3y)145.01%
Cap/Depr(5y)268.95%
Cap/Sales(3y)5.89%
Cap/Sales(5y)11.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3Y3.11%
EPS 5Y65.96%
EPS Q2Q%-42.5%
EPS Next Y-31.19%
EPS Next 2Y-10.6%
EPS Next 3Y5.89%
EPS Next 5YN/A
Revenue 1Y (TTM)12.59%
Revenue growth 3Y25.89%
Revenue growth 5Y22.67%
Sales Q2Q%9.64%
Revenue Next Year9.48%
Revenue Next 2Y8.9%
Revenue Next 3Y8.84%
Revenue Next 5YN/A
EBIT growth 1Y-0.64%
EBIT growth 3Y47.33%
EBIT growth 5YN/A
EBIT Next Year46.18%
EBIT Next 3Y27.41%
EBIT Next 5YN/A
FCF growth 1Y371.76%
FCF growth 3YN/A
FCF growth 5Y99.08%
OCF growth 1Y35.47%
OCF growth 3Y28.35%
OCF growth 5Y54.57%

UNIVERSAL TECHNICAL INSTITUT / UTI Fundamental Analysis FAQ

What is the fundamental rating for UTI stock?

ChartMill assigns a fundamental rating of 5 / 10 to UTI.


What is the valuation status for UTI stock?

ChartMill assigns a valuation rating of 2 / 10 to UNIVERSAL TECHNICAL INSTITUT (UTI). This can be considered as Overvalued.


What is the profitability of UTI stock?

UNIVERSAL TECHNICAL INSTITUT (UTI) has a profitability rating of 7 / 10.


What is the valuation of UNIVERSAL TECHNICAL INSTITUT based on its PE and PB ratios?

The Price/Earnings (PE) ratio for UNIVERSAL TECHNICAL INSTITUT (UTI) is 38.28 and the Price/Book (PB) ratio is 6.08.


Can you provide the expected EPS growth for UTI stock?

The Earnings per Share (EPS) of UNIVERSAL TECHNICAL INSTITUT (UTI) is expected to decline by -31.19% in the next year.